Kessler M, Hiesse C, Hestin D, Mayeux D, Boubenider K, Charpentier B
Department of Nephrology, University Hospital of Nancy, France.
Am J Kidney Dis. 1996 Jul;28(1):99-104. doi: 10.1016/s0272-6386(96)90137-7.
Immunoglobulin A nephropathy (IgAN) frequently recurs in patients after renal transplantation (RT) on a conventional regimen of immunosuppressive therapy, but little is known about the influence of cyclosporine (Cs) on such a recurrence. We studied 84 patients retrospectively who underwent RT for renal failure attributable to IgAN (n = 71) or Henoch-Schönlein purpura nephropathy (HSPN) (n = 13) in two transplantation units, between January 1985 and June 1991 and were treated with Cs. Four patients died 3 months to 8 years after RT. Graft survival was 88% at 1 year, 75.2% at 5 years, and 63% at 8 years. Fifty patients underwent at least one graft biopsy, but studies with immunofluorescence were performed on only 28 (23 IgAN and 5 HSPN). After a mean follow-up of 68.1 +/- 37.2 months, mesangial IgA deposits recurred in 13 of the 28 patients (12 IgAN and 1 HSP) (prevalence, 46.4%). Among the 13 patients with recurrence of IgA deposits, all but 4 had urinary abnormalities. Light microscopy showed mesangial deposits and focal and segmental glomerular changes in 9 cases. Four patients lost their graft function 69 to 119 months after RT, and 2 had severe graft dysfunction. The rates of graft failure and mean serum creatinine at 1, 5, and 8 years were similar in the 13 patients with recurrence and the 15 patients without proven recurrence. In conclusion, Cs did not reduce the incidence or severity of IgAN recurrence. The latter was the cause of graft loss or dysfunction in 46.1 % of the patients with recurrent IgA deposits. Recurrent glomerulonephritis did not influence the 8-year graft survival in patients with IgAN or HSPN, but it may be an important cause of graft loss as evidenced by more extended follow-up.
免疫球蛋白A肾病(IgAN)患者在接受肾移植(RT)后,采用传统免疫抑制治疗方案时该病常复发,但关于环孢素(Cs)对这种复发的影响知之甚少。我们回顾性研究了1985年1月至1991年6月期间在两个移植单位因IgAN(n = 71)或过敏性紫癜性肾炎(HSPN)(n = 13)导致肾衰竭而接受RT并接受Cs治疗的84例患者。4例患者在RT后3个月至8年死亡。1年时移植肾存活率为88%,5年时为75.2%,8年时为63%。50例患者至少接受了一次移植肾活检,但仅对28例(23例IgAN和5例HSPN)进行了免疫荧光研究。平均随访68.1±37.2个月后,28例患者中有13例(12例IgAN和1例HSP)出现系膜IgA沉积复发(发生率为46.4%)。在13例IgA沉积复发的患者中,除4例外均有尿液异常。光镜检查显示9例有系膜沉积及局灶节段性肾小球改变。4例患者在RT后69至119个月移植肾功能丧失,2例有严重移植肾功能障碍。13例复发患者和15例未证实复发患者在1年、5年和8年时的移植肾失功率及平均血清肌酐水平相似。总之,Cs并未降低IgAN复发的发生率或严重程度。在IgA沉积复发的患者中,后者是46.1%的患者移植肾丢失或功能障碍的原因。复发性肾小球肾炎对IgAN或HSPN患者的8年移植肾存活率无影响,但更长时间的随访表明,它可能是移植肾丢失的重要原因。